{"name":"SFJ Pharmaceuticals, Inc.","slug":"sfj-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Bentracimab (PB2452) Infusion","genericName":"Bentracimab (PB2452) Infusion","slug":"bentracimab-pb2452-infusion","indication":"Reversal of unfractionated heparin anticoagulation in patients with acute bleeding or requiring urgent procedures","status":"phase_3"}]}],"pipeline":[{"name":"Bentracimab (PB2452) Infusion","genericName":"Bentracimab (PB2452) Infusion","slug":"bentracimab-pb2452-infusion","phase":"phase_3","mechanism":"Bentracimab is a monoclonal antibody that binds to and neutralizes unfractionated heparin (UFH), rapidly reversing its anticoagulant effects.","indications":["Reversal of unfractionated heparin anticoagulation in patients with acute bleeding or requiring urgent procedures"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNQTlYaEZqN3JLelZ3dHFJaEZTbDZMdVFXQWxvdThGbl9PMk1EZmlGcUl0ZnlQTnF2ZDlYN2xsMmdmcDFPaEhsNFVPSWZhRVB3aDF6MVBXY1d5RmJwT0ozWi1DMkJMYU1UTXRoV2FBaWpib25tZ29tR3NXUXN4TVp0ZFJIUW42RTZiQUl1US16N3UyUlQwNmZsUGhsYnpvYjh4ZEdkLTZlckpiOVhjZmxYSnRtOHhVTWFRdVJmWWZMUWxYOGVJVlJxX2R2dUZJRUQ3SHhNMA?oc=5","date":"2025-12-01","type":"pipeline","source":"The ASCO Post","summary":"Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups - The ASCO Post","headline":"Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOalJtR2w0aVlVUFlGNlo5bEhmT1RxTmRmcm1FV1l0Z0dCQkVrSVN2aWo3dE1ERTBkR00zbzEwWUtGcjFiM2ZTc3NXeHBsbWZEYlU1Qk9QVXpvT21TMy10NlFiWnhXaTh5NXljeVJvalBmMkNBQXpfZzFUWHNJak1FLXlLZHptaGF2M2plZXQ3NjV3cjZLbmVhM3o1Q01CbXRiZFZQTm83Qlcyam93RnBJOFV4ZG9RU3cwZnJZTUhLejdNakZGbFZN?oc=5","date":"2024-10-01","type":"pipeline","source":"prnewswire.com","summary":"PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight - prnewswire.com","headline":"PLK-1 Inhibitors Market to Register Immense Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQR1l2QmN6SEJEVEJLOEctMVVyd191UnYtMDZGcDFnbm1RSFAxVVB6N2hMTUlzaml3TWFDTUxNbF9CTTUxb05VZ2YydEhoT3dMOG9IZk5oVk9iVk5wUDhqVDVyRlZZQ21aVlRkWEpXUnp0MUtxZmE2TzcwYUROUEhFRk54UDJEUk0?oc=5","date":"2024-08-02","type":"regulatory","source":"Yahoo Finance","summary":"FDA has accepted a BLA for bentracimab, the first and only ticagrelor reversal agent, for filing and priority review - Yahoo Finance","headline":"FDA has accepted a BLA for bentracimab, the first and only ticagrelor reversal agent, for filing and priority review","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxPdGJpRUlKNU1nN0JEaDVOdTBVd0JIb1U0VVFqeE82OFdLc0FzdjVKbjh2OVE0b2Z2OEJERE9qNzFua3dmMGZoQmwtVzFHcVpuOUpHajhsXzN0Rjk3bDMtUUtlU3ZjWnVLOUMtSzB2LVhJb2UyQVliV1dZMVFvbnhmSkt3S1pwNHhaMGdKVVF0OVp4MnItYk5RU3hUelZMTXZUOHo2TVdMSXRHbm50QVIwWXRFMlVpMEFBdU5wbDNDaW1oSlQ2VE51ZG9RZkh1enBSN0Z4Wk1vVnFSczVtVDBFTE45eVlqUTdXM3JLSXlwR2d6ZGFQVlE?oc=5","date":"2024-05-14","type":"pipeline","source":"Sixth Street","summary":"Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street - Sixth Street","headline":"Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOcU5KcmpEVHI4VU5fM1hVdklWT2ozM3hUeFYxdkFFREFtZnowVFRPMGtDMEFpMTF1SGRYT2hCT2dFcFBMVWtJcmh0N0dCeUh2TkNlS0U0VHl1WDZIYThqMVdTNC1zaVd3TXBUMGFZdHlHVGtkY2Q2WWY1TmpuTGRlZThYMnlJTFQtMVJyaUVzanNQeEJfUTJxOGg2ek9hX2JxY2VOVW4xU1N3QzViOFdUckdMcDZuNVlhbXBEOVAzVlB4THhU?oc=5","date":"2024-02-27","type":"deal","source":"Fierce Biotech","summary":"Goldilocks and the 'not great, but good enough': Drug development shops offer 'sweet spot' deal alternative - Fierce Biotech","headline":"Goldilocks and the 'not great, but good enough': Drug development shops offer 'sweet spot' deal alternative","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPNFlTck5BVHE0MmtsOUdaVWx0RTR1Q19YWVh0Vl92WnpSeldtYnU2MktxVEFlNGkxWHctVzJ0dUdhc0xHdFZxaUVYV05KYzZadWdYNVIxMzJVb0VSbnVmLWdRdVFHN2VjOGRqWFhpNUtrVG1JZHNVZG5LM2Y5VE92bEN1XzZnamNrWGlHZw?oc=5","date":"2023-05-12","type":"deal","source":"Pharmaceutical Technology","summary":"SERB Pharmaceuticals buys US rights for bentracimab from SFJ - Pharmaceutical Technology","headline":"SERB Pharmaceuticals buys US rights for bentracimab from SFJ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1SVV9VMDNJclhfX3gwbEt1UmdCN0t1aDFKbmZyekZBNGJ0bkRIVzN5Z24zSUtpY281UEZOU3BtSFVpekotdFpLNThfaEVYY0NYU2dtVXptYkh3d0REODlN?oc=5","date":"2023-02-27","type":"trial","source":"Nature","summary":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial - Nature","headline":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung can","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxPNWVkV3ZpVmNnNUFfMEdveWt5UU1hNlc5aktKbUlMMkRMMHNoa2RlN2VyQkgzX09teThCWTF1bE1KLUx6UFFBOFl2dXlGcWlFTTgtMVkwbGpoY0VuOEtwX3JSVDNhQXMyRmR3aUNFMEJWeFQtUTE3S1pIVjdGMWJuVW81VGZKeGJ4N2hEcUpueEJHOGpBdTg4WmNBc3ozWmw5bHF0WGJCTHdObU9MQ2FJVExtQndwX29JYlN1T3phV2UtTlNlU3I2YTBpZjFpODkySXNRNjQ4dnZ6YmM5V18xenZwd3FQdEdYeW9sUnNPRQ?oc=5","date":"2023-01-17","type":"trial","source":"Business Wire","summary":"SFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio Pharmaceuticals - Business Wire","headline":"SFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQOEUyS3JReXNJU3JjTXZ6dGdZRUlTdURVTTItd1duMW91TTVyeF95dlFpQU1OSG5SZzhJSTVJdFNuRXVGYy00MEdqTUcyZ3RpNk1uUXlCRVgxTXZzVGZ2eC14eGR0NXhWRXQ5Z3ZQaU1zcGdXYUVfVG9ISXctMWJhaDJSX0dQM2xLN0cwVjFrSjNwY1pTUTExaWJjZm1TLVF4VjdWN2t1ZXZWczFDclNjZWN3SGhWUQ?oc=5","date":"2022-10-24","type":"trial","source":"BioSpace","summary":"PhaseBio Files for Bankruptcy, Inks Deal to Sell Assets to Unnamed Company (Updated) - BioSpace","headline":"PhaseBio Files for Bankruptcy, Inks Deal to Sell Assets to Unnamed Company (Updated)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPY3lVWldpcmFiY0YxbWFLSkpZMmphcTYyTFp2UFI1NEJWY213V05WWGszSkxwUmd5MXkwMnFaeGsyeXpzVlZ6d1FFRTJOYU15MXUydFJFOEFxS1JLWkFpY2hnQ1hFejVLNkcxOXcycHhRSzh3MWxLcXBJLVB2T0hob0dad01xUjZxMUFSM2FldkNsWHA5UmxkdUtDamY?oc=5","date":"2022-10-23","type":"trial","source":"WSJ","summary":"PhaseBio Files for Bankruptcy Following Blackstone-Backed Partner’s Lawsuit - WSJ","headline":"PhaseBio Files for Bankruptcy Following Blackstone-Backed Partner’s Lawsuit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQNWpVQzV1NndpRkxfbFFGOVItajdOTmtROEFaT3R5QWt0V1FRdnl5c2pqdWItLWt6NGtJRkNwamNQNm05N1F3Q1B6RFJINGZkc2dpbm9sNDlyMVgtdEZSYjJlaXQzN20ydTBoR0IxMjVSZkVYTTBtMllmWXY4RmE2MElLdm4yVl9TMmw4d1FkZElFLXBaZWNvVVMyS2hzTlEySmt2MWh5WnFiSjRrczVxZ0Q3UXBQS0p2OHhiMGZaeGtkUXJLb0p0LXUwY3ZJSXJBSmtobngtYi1wS1NuajBla2FlREZ5UVRVUmJRcnhB?oc=5","date":"2021-02-17","type":"deal","source":"prnewswire.com","summary":"Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer - prnewswire.com","headline":"Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNX2VVczlNYVRwTGlRamhwOFo2THBhN2xramRUMHE4bjBDSHpZX18xZFpOZk5BX2xRLTlKaER6MUgwRzBZRDU4eUxKU29GaTBtM0JFbi1sQkQxSXBKMC1nbXR3OEY2NzF3Snp5RFZ3RzhsaWI4dzE1V2E1VndBanFTSUhfT0ZaVHlNWFUwWG9yc1hmTVVERnFQc0JIazRQWTI1MXQ5ZjV5Y1RaUmc?oc=5","date":"2021-02-17","type":"deal","source":"BioSpace","summary":"Nektar Secures Collaborative Deal with SFJ to Advance Head and Neck Cancer Therapy - BioSpace","headline":"Nektar Secures Collaborative Deal with SFJ to Advance Head and Neck Cancer Therapy","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}